Gut Healing Stack: BPC-157 + KPV + Larazotide
Last updated: 2026-03-03
The Gut Healing Stack combines oral BPC-157, KPV, and Larazotide into a targeted protocol for intestinal repair, inflammation reduction, and gut barrier restoration. This stack addresses the three core dysfunctions underlying most gut disorders: mucosal damage, chronic inflammation, and increased intestinal permeability ("leaky gut").
BPC-157 — administered orally to maximize gastrointestinal contact — provides mucosal healing and cytoprotection. KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, delivers potent anti-inflammatory effects by inhibiting NF-kB activation in intestinal epithelial cells. Larazotide acetate (AT-1001) is a synthetic octapeptide tight junction regulator that directly addresses intestinal permeability by modulating zonulin-mediated paracellular transport.[1]
This guide covers the complete gut healing protocol including dosing, mechanism synergy, timeline expectations, cycling recommendations, and research evidence. For more on BPC-157's gut-specific research, see our BPC-157 gut healing research review. All information is for educational purposes only and should not be construed as medical advice.
Compounds in This Stack
BPC-157 (Oral)
Mucosal healing, cytoprotection, angiogenesis in gut tissue
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice. Unlike most peptides, BPC-157 is remarkably stable in gastric acid — making oral administration not just viable but specifically advantageous for gut healing. Oral BPC-157 provides direct contact with the gastrointestinal mucosa, concentrating its effects where they are most needed.[1]
Mechanism in this stack: Oral BPC-157 acts directly on the GI tract to accelerate mucosal healing, protect against NSAID-induced gastric damage, promote angiogenesis in damaged gut tissue via VEGF upregulation, and modulate the NO system to regulate intestinal inflammation. It also interacts with the dopamine and serotonin systems in the enteric nervous system (the "gut brain"), potentially influencing gut motility and the gut-brain axis. In this stack, BPC-157 is the primary tissue repair agent.
| Parameter | Detail |
|---|---|
| Research Dosage | 500–1000 mcg per day (oral) |
| Route | Oral (capsule or liquid on empty stomach) |
| Frequency | Once or twice daily |
| Best Timing | 30 minutes before breakfast and/or before bed |
| Why Oral? | Direct mucosal contact; stable in gastric acid (unique among peptides) |
KPV
Anti-inflammatory, NF-kB inhibition, intestinal immune modulation
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (alpha-MSH). Despite being only three amino acids long, KPV retains the full anti-inflammatory activity of the parent hormone while being small enough to cross cell membranes and resist enzymatic degradation in the GI tract. Research has demonstrated its efficacy in preclinical models of inflammatory bowel disease.[2]
Mechanism in this stack: KPV enters intestinal epithelial cells and directly inhibits NF-kB activation — the master transcription factor driving inflammatory gene expression in the gut. It reduces production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in the intestinal mucosa, dampens neutrophil infiltration into inflamed tissue, and modulates macrophage polarization toward anti-inflammatory (M2) phenotypes. In this stack, KPV provides the anti-inflammatory layer that allows BPC-157's tissue repair to proceed in a less hostile environment. See our KPV anti-inflammatory guide for a deep dive.
| Parameter | Detail |
|---|---|
| Research Dosage | 200–500 mcg per day (oral or subcutaneous) |
| Route | Oral (preferred for gut), subcutaneous, or rectal (for lower GI) |
| Frequency | Once or twice daily |
| Half-Life | Short; tripeptide rapidly absorbed |
| Note | Oral administration provides direct intestinal anti-inflammatory contact |
Larazotide Acetate (AT-1001)
Tight junction regulation, intestinal permeability reduction, zonulin antagonism
Larazotide acetate (AT-1001) is a synthetic octapeptide derived from Vibrio cholerae zonula occludens toxin (ZOT). It acts as a competitive antagonist at the zonulin receptor, which regulates tight junctions between intestinal epithelial cells. Larazotide has been studied in Phase 3 clinical trials for celiac disease and represents one of the most clinically advanced peptides targeting intestinal permeability.[3]
Mechanism in this stack: Larazotide directly addresses "leaky gut" — the increased intestinal permeability that allows undigested food particles, bacterial endotoxins, and other antigens to pass through the gut barrier into systemic circulation. It works by blocking zonulin (a protein that opens tight junctions) from binding to its receptor, keeping tight junctions closed. This mechanism is distinct from both BPC-157 (which heals tissue) and KPV (which reduces inflammation) — Larazotide specifically restores barrier function.
| Parameter | Detail |
|---|---|
| Research Dosage | 0.5–1 mg three times daily (with meals) |
| Route | Oral (capsule, taken with meals) |
| Frequency | Three times daily (before each main meal) |
| Clinical Trial Dosage | 0.5 mg TID showed optimal results in Phase 2b celiac trials |
| Note | Not yet FDA-approved; Phase 3 trials ongoing for celiac disease |
How They Work Together
The Gut Healing Stack targets the three core dysfunctions that underlie most gut disorders — tissue damage, chronic inflammation, and barrier permeability — through three peptides that address each dysfunction independently. This multi-target approach is essential because gut disorders are rarely caused by a single mechanism.
Layer 1: Mucosal Repair (BPC-157 Oral)
BPC-157's gastric acid stability makes it uniquely suited for oral gut healing. When taken orally, it provides direct contact with damaged GI mucosa from the esophagus to the colon. Its promotion of angiogenesis (VEGF), collagen remodeling (EGR-1), and nitric oxide modulation accelerates the physical repair of ulcers, erosions, and mucosal damage. Preclinical studies have shown BPC-157 protects against and heals damage from NSAIDs, alcohol, stress, and inflammatory bowel conditions.[1]
Layer 2: Inflammation Control (KPV)
Tissue repair cannot proceed efficiently in a chronically inflamed environment. KPV's NF-kB inhibition reduces the inflammatory burden in the intestinal wall, creating a permissive environment for BPC-157's repair mechanisms to work. This is analogous to putting out a fire before rebuilding the structure. KPV also modulates macrophage polarization — shifting intestinal immune cells from pro-inflammatory (M1) to tissue-repairing (M2) phenotypes, which directly supports the healing process.[2]
Layer 3: Barrier Restoration (Larazotide)
Even after mucosal damage is repaired and inflammation is controlled, compromised tight junctions can allow continued translocation of antigens, endotoxins, and food particles into systemic circulation — perpetuating immune activation and systemic inflammation. Larazotide's zonulin receptor antagonism directly addresses this by keeping tight junctions closed, restoring the selective permeability that defines a healthy gut barrier. This prevents the cycle of barrier breach → immune activation → inflammation → barrier breach that characterizes chronic gut disorders.[3]
The Three-Target Advantage
Most gut healing protocols focus on only one or two of these mechanisms. Anti-inflammatory supplements reduce inflammation but don't repair tissue. Gut-healing nutrients (like L-glutamine) support repair but don't address tight junction permeability. This stack simultaneously repairs the tissue (BPC-157), controls the inflammation (KPV), and seals the barrier (Larazotide) — addressing the complete pathophysiology of leaky gut and related conditions. For related content, see our BPC-157 dosage guide and peptides for healing goals page.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Protocol & Dosage Schedule
Dosage Schedule
| Phase | BPC-157 (Oral) | KPV | Larazotide | Duration |
|---|---|---|---|---|
| Introduction | 500 mcg oral AM | 200 mcg oral AM | 0.5 mg with meals (3x/day) | Weeks 1–2 |
| Active Phase | 500 mcg oral AM + PM | 250–500 mcg oral AM + PM | 0.5–1 mg with meals (3x/day) | Weeks 3–8 |
| Maintenance | 500 mcg oral AM | 200 mcg oral AM | 0.5 mg with meals (as needed) | Weeks 9–12 |
Cycle Length
8–12 weeks for a full gut healing cycle. Many functional medicine practitioners recommend reassessing gut permeability markers (lactulose/mannitol test, zonulin levels, or calprotectin) at weeks 4 and 8 to gauge progress. BPC-157 can be continued independently if healing is progressing but incomplete. Larazotide may be needed longer-term for individuals with ongoing gluten exposure or celiac disease. A 4-week break from the full stack between cycles is recommended.
Timing & Administration
Morning protocol (empty stomach is key):
- 30 minutes before breakfast: BPC-157 500 mcg oral — empty stomach maximizes mucosal contact
- Same time: KPV 200–500 mcg oral — co-administered with BPC-157
- With breakfast: Larazotide 0.5–1 mg — taken with meals to address food-triggered permeability
Midday and evening:
- With lunch: Larazotide 0.5–1 mg
- With dinner: Larazotide 0.5–1 mg
- Before bed (active phase): BPC-157 500 mcg oral + KPV 250 mcg oral — overnight healing window
Dietary considerations: This stack works best alongside a gut-supportive diet. During the first 4 weeks, consider reducing or eliminating known gut irritants: alcohol, NSAIDs, refined sugar, processed seed oils, and any personal food sensitivities. Adequate fiber from whole foods supports the microbiome environment in which these peptides operate. Bone broth, fermented foods, and omega-3 rich foods complement the protocol.
What to Expect
Gut healing is a gradual process. Unlike injury healing where you might feel improvement within days, gut barrier restoration involves cellular turnover, immune modulation, and microbiome adjustments that take weeks. Patience and consistency are essential.
| Timeframe | Expected Observations |
|---|---|
| Week 1 | Reduced bloating and abdominal discomfort (KPV anti-inflammatory effect). Improved stool consistency for some users. Some may experience temporary GI adjustment symptoms. |
| Weeks 2–3 | More consistent bowel movements. Reduced post-meal bloating and gas. Less food reactivity (fewer symptoms from previously problematic foods). Improved energy as systemic inflammation decreases. |
| Weeks 4–6 | Meaningful improvement in gut symptoms. Reduced food sensitivities. Improved nutrient absorption (better skin, nails, energy). If testing, permeability markers should show improvement. |
| Weeks 8–12 | Substantial gut barrier restoration. Significantly reduced food reactivity. Improved overall systemic inflammation markers. Many users report resolution of symptoms that were previously chronic. |
Safety & Contraindications
Known Side Effects
This stack is entirely oral, which reduces injection-related risks. All three compounds have generally favorable safety profiles in available research.
BPC-157 (oral) reported side effects:
- Mild nausea (usually resolves within the first few days)
- Temporary changes in bowel habits during initial adjustment
- Headache (infrequent)
KPV reported side effects:
- Generally very well tolerated as a short tripeptide
- Mild GI adjustment symptoms during the first week
- Rare: skin flushing (melanocortin pathway, usually only with injectable use)
Larazotide reported side effects (from clinical trial data):
- Headache (most commonly reported in Phase 2 trials)
- Upper respiratory tract infection (in some trial participants)
- Nausea (mild, infrequent)
- Generally well-tolerated — the safety profile in Phase 2/3 trials was comparable to placebo
Contraindications and Cautions
- Active GI bleeding: If you have active gastrointestinal bleeding, seek medical attention before starting any gut healing protocol. BPC-157 promotes angiogenesis which could theoretically worsen active bleeding.
- Inflammatory bowel disease (IBD): This stack may be supportive for IBD, but should only be used as a complement to (not replacement for) conventional IBD treatment under medical supervision.
- Cancer history: BPC-157 promotes angiogenesis. Individuals with GI cancer history should avoid this stack.
- Celiac disease: Larazotide was specifically developed for celiac disease, but it is not a substitute for a gluten-free diet. It may reduce symptoms from accidental gluten exposure but cannot fully prevent gluten-mediated damage in confirmed celiac disease.
- Pregnancy and breastfeeding: No safety data for any compound in this stack during pregnancy or lactation. Avoid entirely.
- Concurrent medications: Larazotide affects intestinal permeability, which could theoretically alter absorption of oral medications. Maintain consistent timing between this stack and any prescription medications, and inform your healthcare provider.
Quality and Sourcing
Oral peptides must meet higher purity standards since they pass through the entire GI tract. BPC-157 for oral use should have 98%+ purity (HPLC verified) and be formulated in acid-resistant capsules or as a stable liquid. KPV is available in oral capsule form from specialty peptide suppliers. Larazotide is a research compound — source from suppliers who provide COA documentation with mass spectrometry confirmation.
Important: None of these peptides is FDA-approved for human use (Larazotide has completed Phase 2 trials and is in Phase 3 for celiac disease). This information is for educational purposes only. Individuals with diagnosed GI conditions should work with a gastroenterologist or functional medicine practitioner.
Where to Buy These Peptides
Third-party tested, research-grade peptides from our trusted supplier. Use code PEPTIDESINSIDER for 15% off.
Frequently Asked Questions
References
- Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al.. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.
- Leffler DA, Kelly CP, Abdallah HZ, et al.. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. American Journal of Gastroenterology, 2012.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Related Stacks
Individual Compound Guides
Peptides Insider Editorial Team
Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.